Onyx Biotec Ltd (ONYX) is currently trading at 37.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Onyx Biotec Limited is a contract manufacturer of pharmaceutical products, primarily sterile water for injections (SWFI), dry powder injections and dry syrup formulations, operating two manufacturing units in Solan, Himachal Pradesh, supplying major Indian pharma companies and offering end‑to‑end regulatory dossier preparation and manufacturing services. The company raised net IPO proceeds of Rs. 2,538.02 lakhs (Nov 2024) and disclosed targeted use of funds to upgrade Unit I, install a high‑speed cartoning packaging line at Unit II, and prepay loans; management reports no deviation in utilisation and parked unutilised proceeds in fixed deposits. Operational scale includes legacy FFS technology for SWFI and a 2017 capacity uplift from ~130 million to ~230 million units per annum; Unit II began manufacturing in 2023 and received WHO‑GMP certification in May 2024, positioning Onyx Biotec for regulated market supply and export opportunities. Financially, H1 ended September 30, 2025 recorded a reported net loss of Rs. 90.05 lakhs, negative operating cash flow of Rs. 419.88 lakhs, and closing cash and equivalents of Rs. 718.86 lakhs; the company also created a provision for doubtful debts amounting to Rs. 150 lakhs during the period.

Over the past 52 weeks, Onyx Biotec Ltd has traded between a low of ₹24.20 and a high of ₹49.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Onyx Biotec Ltd has a market capitalization of approximately 67.09. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Onyx Biotec Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -319.48 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 67.09 Cr, Onyx Biotec Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Onyx Biotec Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Onyx Biotec Ltd is -319.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.